4:持股变动声明-董事 Novak Alfred J
Pasithea Therapeutics | 4/A:持股变动声明(修正)-高管 Marques Tiago
Pasithea Therapeutics | 4/A:持股变动声明(修正)-董事 Dumesnil Simon
Pasithea Therapeutics | 4/A:持股变动声明(修正)-高管 Schneiderman Daniel H
Pasithea Therapeutics | 4/A:持股变动声明(修正)-董事 Leahy Emer
Pasithea Therapeutics | 4/A:持股变动声明(修正)-董事 Novak Alfred J
Pasithea Therapeutics | 4/A:持股变动声明(修正)-高管 Currie Graeme Martin
Pasithea Therapeutics | 4/A:持股变动声明(修正)-董事 STEINMAN LAWRENCE
Pasithea Therapeutics | 4:持股变动声明-董事 STEINMAN LAWRENCE
Pasithea Therapeutics | 4:持股变动声明-高管 Schneiderman Daniel H
Pasithea Therapeutics | 4:持股变动声明-董事 Novak Alfred J
Pasithea Therapeutics | 4:持股变动声明-高管 Marques Tiago
Pasithea Therapeutics | 4:持股变动声明-董事 Leahy Emer
Pasithea Therapeutics | 4:持股变动声明-董事 Dumesnil Simon
Pasithea Therapeutics | 4:持股变动声明-高管 Currie Graeme Martin
Pasithea Therapeutics | 3:首次持股声明-高管 Currie Graeme Martin
Pasithea Therapeutics | SC 13D:超过5%持股股东披露文件-Lawrence Steinman(6.0%)
Pasithea Therapeutics | 4/A:持股变动声明(修正)-董事 STEINMAN LAWRENCE
Pasithea Therapeutics | 4:持股变动声明-董事 STEINMAN LAWRENCE
Pasithea Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Paul B. Manning(11.3%),PD Joint Holdings, LLC, Series 2016-A(11.3%)等
暂无数据